Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3
- 1 February 2001
- journal article
- Published by Elsevier in Transplantation Proceedings
- Vol. 33 (1-2) , 1057-1058
- https://doi.org/10.1016/s0041-1345(00)02414-3
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- ATGAM Versus OKT3 Induction Therapy in Cadaveric Kidney Transplantation: Patient and Graft Survival, CD3 Subset, Infection, and Cost AnalysisTransplantation Proceedings, 1998
- LONG-TERM FUNCTION AND SURVIVAL OF ELDERLY DONOR KIDNEYS TRANSPLANTED INTO YOUNG ADULTS1Transplantation, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- CORTICOSTEROID INHIBITION OF THE OKT3-INDUCED CYTOKINE-RELATED SYNDROMETransplantation, 1991